The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
(Adds details about Novartis investigation; updates shares)
NEW YORK, Aug 7 (Reuters) - Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation.
Novartis faces possible civil or criminal penalties from the U.S. Food and Drug Administration, which said on Tuesday that some data was manipulated from early testing of Zolgensma, the world's most expensive treatment. The FDA said the company was aware of the problems for as much as two months before the drug's U.S. approval.
"We made the decision to progress our quality investigation prior to informing FDA and other regulatory authorities so that we could provide the best information and technical analysis, which we did promptly on completion on June 28," Novartis Chief Executive Vasant Narasimhan said on a conference call with analysts.
Narasimhan said the decision to delay notifying regulators was not tied to timing of the drug's approval process.
Zolgensma was approved in late May as a one-time treatment for spinal muscular atrophy (SMA), the leading genetic cause of death in infants.. The disease often leads to paralysis, breathing difficulty and death within months for babies born with the disease.
The FDA said on Tuesday it did not believe the manipulation affects the safety or later human testing of the drug, and it believes the treatment should remain on the market. The manipulated data was used to illustrate comparability between an early version of Zolgensma and the current version of the treatment, which is manufactured using a different process.
Narasimhan said Novartis received the allegations of data manipulation in mid-March, more than two months before the gene therapy's U.S. approval.
The company finished a preliminary investigation into the allegations in early May, confirming data discrepancies and raising data integrity concerns, the CEO said.
Novartis followed that up with a "full technical quality investigation" of the data. On June 28, Narasimhan said the company communicated its findings to the FDA.
It notified regulators in Europe and Japan shortly afterward, and does not expect the issues to effect timing of Zolgensma's development there.
Novartis said it was in the process of "exiting" the scientists responsible for the manipulation and does not believe the issue extends beyond those scientists.
Zolgensma is no longer on track for accelerated approval in Europe, but the company said it still expects approval there in the fourth quarter.
Shares of the Swiss drugmaker were down 3.4% to 85.64 Swiss francs on Wednesday. (Reporting by Michael Erman; Editing by David Gregorio and Bill Berkrot)